30 ноября, 17:56

Key Pharma Players With HIV Focus Ahead of World Aids Day

We take a look at some of the major pharma companies in the HIV market that are developing drugs to address the life-threatening disease.

30 ноября, 01:45

Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know

Johnson & Johnson (JNJ) closed the most recent trading day at $145.85, moving -0.4% from the previous trading session.

30 ноября, 00:47

Theravance Pipeline Strong, Plans Yupelri Launch by Year End

Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.

29 ноября, 16:10

4 Big Pharma Stocks to Add to Your Portfolio in December

The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.

29 ноября, 15:57

The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture

The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture

29 ноября, 01:48

Novartis (NVS) Receives EC Approval for Neulasta Biosimilar

Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.

Выбор редакции
28 ноября, 18:20

Theravance's Respiratory Disease JAK Inhibitor Enters Phase I

Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.

Выбор редакции
16 июля, 14:42

Продукция Johnson & Johnson признана вызывающей рак

Товары американской компании Johnson & Johnson признаны вызывающими рак. Данное решение было вынесено судом присяжных города Сент-Луис в штате Миссури. Об этом пишет МедикФорум. Пострадавшим от их использования женщинам будет выплачена гигантская сумма компенсации в […]

26 мая, 20:43

КАПИТАЛИЗАЦИИ БОГАТЕЙШИХ КОМПАНИЙ МИРА

К сожалению, акции эмитентов РФ не могут порадовать рекордами ТЕПЕРЬ ИНТЕРЕСНОЕ, КАПИТАЛИЗАЦИИ БОГАТЕЙШИХ КОМПАНИЙ МИРА по данным за 2017-18г. Starbucks — 84.6 млрд. $ Nike — 91.2 млрд. $ Bayer — 94.4 млрд. $ Mscdonalds — 106.4 млрд. $ Loreal — 107.5 млрд. $ Boeing-108.8 млрд. $ Siemens — 109.8 млрд. $ KraftHeinz  — 110.4 млрд. $ Mastercadr -121.3 млрд. $ BritishAmericanTobaco — 123.8 млрд. $ Total — 128.1 млрд. $ Pepsico — 159.4 млрд. $ IBM — 162.4 млрд. $ Cisco- 165.1 млрд. $ Intel — 170 млрд. $ Toyota — 175 млрд. $ WaltDisney -178 млрд. $ Cocacola — 182 млрд. $ Pfizer — 203 млрд. $ Chevron — 206 млрд. $ Visa — 206 млрд. $ Walmart — 221.1 млрд. $ P&G — 228.1 млрд. $ Nestle — 229.5 млрд. $ Bank of America — 231 млрд. $ Samsung — 254.3 млрд. $ Alibaba — 264 млрд. $   Johnson&Johnson — 338.6 млрд. $ Exxon Mobil — 343.2 млрд. $ FB — 407.3 млрд. $ Berkshire Hathaway — 409.9 млрд. $ 2018 год  Intel — 259 млрд. $ Alibaba - 512 млрд. $ Microsoft — 751 млрд. $ Alphabet — 765 млрд. $ Amazon — 782 млрд. $ Apple — 933 млрд. $ (годовой бюджет Великобритании) P.S.

03 апреля, 14:52

17 Advertisers That Have Dropped Laura Ingraham’s Fox News Show

Laura Ingraham is paying the price for mocking shooting survivor David Hogg on social media. Advertisers are ditching her Fox News show in a show of solidarity.

Выбор редакции
03 апреля, 14:44

Журналистка Fox назвала плаксой подростка, пережившего стрельбу в школе

Ведущая телеканала Fox Лора Ингрэм назвала нытиком 17-летнего Дэвида Хогга, которому удалось уцелеть во время стрельбы в школе в Парклэнде, штат Флорида. Молодой человек в ответ призвал рекламодателей бойкотировать популярное консервативное СМИ. Многие компании разорвали контракты с Fox.

02 апреля, 17:02

Shire's Stock Continues to Rise as Takeda Sets Eyes On it

Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.

Выбор редакции
01 апреля, 14:18

Better Buy: AbbVie Inc. vs. Johnson & Johnson

Which big pharma stock wins when it comes to growth, income, and value?

30 марта, 17:18

Florida shooting survivor Hogg won't accept Ingraham's apology over mocking tweet

Florida shooting survivor David Hogg declined on Friday to accept Fox News host Laura Ingraham’s apology over a tweet mocking him, saying she’s only expressing remorse because a flurry of advertisers dropped her program. Hogg, who called for companies to boycott the talk show host after she derided the Marjory Stoneman Douglas High School student over several college application rejections, framed Ingraham’s apology as insufficient and self-serving. Pressed on whether he'd accept her apology, he replied, "No."“She’s only apologizing after a third of her advertisers pulled out and I think it’s really disgusting the fact that she basically tried promoting her show after apologizing — or ‘apologizing’ to me,” Hogg told CNN during an interview Friday. Ingraham issued an apology for her remarks Thursday after several advertisers announced they were cutting ties with the program.“Any student should be proud of a 4.2 GPA —incl. @DavidHogg111,” the host tweeted. “On reflection, in the spirit of Holy Week, I apologize for any upset or hurt my tweet caused him or any of the brave victims of Parkland.”The Fox News host went on to note that she interviewed Hogg on her program in the aftermath of the massacre in Parkland, where a gunman killed 17 and injured several others last month. Ingraham extended an invitation to the student to return to show “for a productive discussion.” Hogg on Thursday praised advertisers for heeding his denunciation of Ingraham’s remarks. Hogg, who gained national prominence after the shooting as an advocate against gun violence, listed several of Ingraham's top advertisers on Twitter after her initial comments. “I think it’s great that corporate American is standing with me and the rest of my friends, because when you come against any one of us, whether it be me or anybody else, you’re coming against all of us,” he said.At least eleven companies have said they will cease to run ads on Ingraham’s program in response to her tweet. TripAdvisor, Nutrish, Expedia, Nestle, Wayfair and Hulu said they will stop their ads on “The Ingraham Angle,” which airs daily on the Fox News Channel at 10 p.m. Johnson & Johnson, Jenny Craig and Stitch Fix told HuffPost they would follow suit. According to the Daily Beast, Jos. A. Bank and Office Depot said they had no plans to buy future ads for the show. The moves came after Ingraham shared a report on Twitter that Hogg’s college application had been rejected by certain schools. “David Hogg Rejected By Four Colleges To Which He Applied and whines about it,” the Fox News host wrote Wednesday.Hogg told CNN that Ingraham’s remarks were part of an effort to “distract” from the debate on gun violence. “From a journalistic standpoint I would say she needs to be more objective and stand down because I am not the issue here,” he said. “The issue needs to be gun violence in America. But what she’s trying to do is to distract from that and I hate it.”

29 марта, 22:21

Tackle Market Uncertainty With These 3 Quality Dividend ETFs

Consider these three dividend ETFs for your portfolio to fight growing market uncertainty.

29 марта, 18:17

Why Is Integra LifeSciences (IART) Up 3.6% Since Its Last Earnings Report?

Integra LifeSciences (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

29 марта, 14:11

The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton

The Zacks Analyst Blog Highlights: Johnson & Johnson, Intel, Procter & Gamble, Caterpillar and Halliburton

28 марта, 23:49

Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble

Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble

28 марта, 18:46

3 Dow Stocks to Buy Amid Tech Selloff

The Dow opened slightly higher on Wednesday morning as investors look to rebound from a brutal day of trading Tuesday that saw tech stocks drop en masse. With this in mind, the Dow 30 stocks include plenty of attractive options today. Check out these three Dow stocks to buy now!

27 марта, 17:08

Protagonist Therapeutics Stalls Ulcerative Colitis Study

Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.

16 февраля, 21:59

Ужасный конец. Почему миллиардер Галицкий решил оставить «Магнит»

На пресс-конференции, посвященной сделке, основатель «Магнита» с трудом сдерживал слезы. Попрощаться с ним в головной офис торговой сети в Краснодаре пришли сотни человек. Forbes вспоминает, как миллиардер создавал свое детище

19 июня 2017, 19:33

США объявили войну фармкомпаниям

Наркоторговцам в США объявлена война еще с 80-х годов, в результате чего правоохранительные органы крайне жестко работают с представителями этой отрасли криминального мира.